Serial 98196013
Live / Allowed — Third extension granted (statement of use) (as of 29 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Sept 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 98196013
- Mark type
- Design / logo
- Filed
- 25 Sept 2023
- Published for opposition
- 31 Dec 2024
- Attorney of record
- Christina Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; pharmaceutical preparations for the use in gene therapy for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; preparations for detecting mutation in RNA genes for medical purposes
- Class 042 — Scientific and technological services: development of gene-based medicines; gene therapy and modulation research; laboratory research in the fields of degrading and enhancing RNA including exon skipping and rescue genetic lesions; Medical and scientific research in the fields of genetics, genomics, gene modulation and genetic engineering; DNA and RNA analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics and gene modulation
Owner
- Remix Therapeutics Inc., Watertown, MA, US
- Remix Therapeutics Inc., Cambridge, MA, US
Prosecution history
- 30 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Jul 2026 — SOU EXTENSION 3 GRANTED
- 29 Jul 2026 — SOU EXTENSION 3 FILED
- 29 Jul 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2026 — SOU EXTENSION 2 GRANTED
- 25 Feb 2026 — SOU EXTENSION 2 FILED
- 25 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Aug 2025 — SOU EXTENSION 1 GRANTED
- 25 Aug 2025 — SOU EXTENSION 1 FILED
- 25 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 23 Apr 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 23 Apr 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 23 Apr 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED